Concise Review: Guidance in Developing Commercializable Autologous/Patient-Specific Cell Therapy Manufacturing

Author:

Eaker Shannon12,Armant Myriam13,Brandwein Harvey14,Burger Scott15,Campbell Andrew16,Carpenito Carmine17,Clarke Dominic18,Fong Timothy19,Karnieli Ohad110,Niss Knut111,Van't Hof Wouter112,Wagey Ravenska113

Affiliation:

1. International Society for Cellular Therapy, Knoxville, Tennessee, USA

2. GE Healthcare, Knoxville, Tennessee, USA

3. Harvard University, Boston, Massachusetts, USA

4. Pall Corporation, Port Washington, New York, USA

5. Advanced Cell and Gene Therapy, Chapel Hill, North Carolina, USA

6. Life Technologies, Grand Island, New York, USA

7. Lonza, Walkersville, Maryland, USA

8. Charter Medical, Ltd., Winston-Salem, North Carolina, USA

9. Progenitor Cell Therapy, Allendale, New Jersey, USA

10. Pluristem Therapeutics, Haifa, Israel

11. Novartis Pharmaceuticals Corp., Morris Plains, New Jersey, USA

12. Athersys, Cleveland, Ohio, USA

13. StemCell Technologies, Vancouver, British Columbia, Canada

Abstract

Abstract Cell therapy is poised to play an enormous role in regenerative medicine. However, little guidance is being made available to academic and industrial entities in the start-up phase. In this technical review, members of the International Society for Cell Therapy provide guidance in developing commercializable autologous and patient-specific manufacturing strategies from the perspective of process development. Special emphasis is placed on providing guidance to small academic or biotech researchers as to what simple questions can be addressed or answered at the bench in order to make their cell therapy products more feasible for commercial-scale production. We discuss the processes that are required for scale-out at the manufacturing level, and how many questions can be addressed at the bench level. The goal of this review is to provide guidance in the form of topics that can be addressed early in the process of development to better the chances of the product being successful for future commercialization.

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3